Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,385.52 -32.16 -0.22%
TOPIX 1,164.41 -2.14 -0.18%
HANG SENG 22,776.12 80.11 0.35%

Horizon Pharma to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results on May 10, 2013


Horizon Pharma to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results on May 10, 2013

DEERFIELD, IL -- (Marketwired) -- 04/29/13 -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its first quarter 2013 financial results will be released on Friday, May 10, 2013. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update.

The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 35984880. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 35984880.

About Horizon Pharma Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire, in-license and/or co-promote additional innovative medicines where it can execute a targeted commercial approach in specific therapeutic areas while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.

Contacts: Robert J. De Vaere Executive Vice President and Chief Financial Officer investor-relations@horizonpharma.com

Investors Kathy Galante Burns McClellan, Inc. 212-213-0006 kgalante@burnsmc.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement